- Have recurrent or persistent endometrial cancer (endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, mixed epithelial carcinoma or adenocarcinoma not otherwise specified [NOS])
- Female age ≥ 18
- Performance Status [ECOG/Karnofsky] of 0, 1 or 2
- Have a somatic PIK3CA gene mutation
- Have at least one "target lesion" to be used to assess response on this protocol
- Have had at least one prior chemotherapeutic regimen for management of endometrial carcinoma
- Have recovered from effects of recent surgery, radiotherapy, or chemotherapy
Ineligibility Criteria
- Have had prior therapy with any PI3K/AKT/mTor pathway inhibitor
- Have the following histologies: mucinous, squamous, sarcomas, carcinosarcomas, clear cell
- Severe, active co-morbidity
- History of, or current autoimmune disease
- HIV infection
- Hepatitis B (HBV) or hepatitis C (HCV)
- Previous or concurrent history of malignancies within 5 years prior to study treatment except for curatively treated: Cervical carcinoma in situ, Non-melanoma skin cancer, Superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria])
Please contact Legacy Oncology Research for additional study inclusion/exclusion information.